This week, six pharmaceutical stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

This week, NuPathe Inc. (PATH) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. For more information, get Portfolio Grader’s complete analysis of PATH stock.

This week, GW Pharmaceuticals PLC Sponsored ADR (GWPH) pushes up from a C to a B rating. Shares of the stock have been changing hands at an unusually rapid pace, three times the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of GWPH stock.

Watson Pharmaceuticals (WPI) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.

This week, Paratek Pharmaceuticals Inc’s (PRTK) ratings are up from a B last week to an A. For more information, get Portfolio Grader’s complete analysis of PRTK stock.

Cardiome Pharma (CRME) gets a higher grade this week, advancing from a C last week to a B. Cardiome Pharma focuses on the discovery, development, and commercialization of drugs to treat or prevent cardiovascular and other diseases. For more information, get Portfolio Grader’s complete analysis of CRME stock.

AbbVie, Inc. (ABBV) improves from a C to a B rating this week. AbbVie, a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. For more information, get Portfolio Grader’s complete analysis of ABBV stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.